Results 221 to 230 of about 258,661 (263)
Some of the next articles are maybe not open access.
Annals of Internal Medicine, 2020
Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507-19. 32187462.
Jennifer, Clark, Victor, Montori
openaire +2 more sources
Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507-19. 32187462.
Jennifer, Clark, Victor, Montori
openaire +2 more sources
Info Diabetologie, 2016
Alirocumab von Sanofi senkt den LDL-Cholesterin (LDL-C)-Spiegel bei schwerer Hypercholesterinamie sehr effektiv. Von dem PCSK9-Hemmer konnen Patienten mit hohem kardiovaskularem Risiko und hohem LDL-C-Spiegel trotz maximaler lipidsenkender Standardtherapie profitieren.
openaire +1 more source
Alirocumab von Sanofi senkt den LDL-Cholesterin (LDL-C)-Spiegel bei schwerer Hypercholesterinamie sehr effektiv. Von dem PCSK9-Hemmer konnen Patienten mit hohem kardiovaskularem Risiko und hohem LDL-C-Spiegel trotz maximaler lipidsenkender Standardtherapie profitieren.
openaire +1 more source
Reduction of Serum LDL-C Levels
American Journal of Cardiovascular Drugs, 2003The association between elevated serum cholesterol levels and cardiovascular risk was established several decades ago by studies such as the Framingham study and the Multiple Risk Factor Intervention Trial (MRFIT). Both primary and secondary prevention trials of cholesterol lowering, using HMG-CoA reductase inhibitors, have demonstrated clear benefits ...
openaire +2 more sources
European Journal of Preventive Cardiology, 2013
Reducing low-density lipoprotein cholesterol (LDL-C) levels decreases cardiovascular risk in direct proportion to the decrease in LDL-C.The aim of this study was to assess the importance of baseline LDL-C and choice and dose of statin in achievement of LDL-C goals of 100 and 70 mg/dl, using a novel statistical model.
Palmer, M. +4 more
openaire +3 more sources
Reducing low-density lipoprotein cholesterol (LDL-C) levels decreases cardiovascular risk in direct proportion to the decrease in LDL-C.The aim of this study was to assess the importance of baseline LDL-C and choice and dose of statin in achievement of LDL-C goals of 100 and 70 mg/dl, using a novel statistical model.
Palmer, M. +4 more
openaire +3 more sources
Duale LDL-C-Senkung in Fixkombination
Info Diabetologie, 2015Viele Typ-2-Diabetiker haben eine Fettleber mit dem Vollbild des metabolischen Syndroms. Um ihr besonders hohes kardiovaskulares Risiko zu reduzieren, ist die starke LDL-Cholesterinsenkung (LDL-C) wesentlich. Mit neuen Fixkombinationen von Statinen mit Ezetimib stehen hierfur sehr effektive Optionen zur Verfugung.
openaire +1 more source
Assessment of LDL-C Calculation Using the Newly Adopted NIH LDL-C Equation in a Pediatric Population
Clinical Chemistry, 2022Ka Keung, Chan, Jane A, Dickerson
openaire +2 more sources
Lipoprotein(a) cholesterol contribution to “LDL-C” lowers the ability of a statin to reduce “LDL-C”
Atherosclerosis, 2022openaire +1 more source
Clinical Chemistry
Abstract Background Patients at high risk for Atherosclerotic Cardiovascular Disease (ASCVD), who do not achieve adequate lowering of LDL-cholesterol (LDL-C) with maximally tolerated statins or who are statin-intolerant, are often treated with proprotein convertase subtilisin/kexin (type 9) serine ...
M Sampson +4 more
openaire +1 more source
Abstract Background Patients at high risk for Atherosclerotic Cardiovascular Disease (ASCVD), who do not achieve adequate lowering of LDL-cholesterol (LDL-C) with maximally tolerated statins or who are statin-intolerant, are often treated with proprotein convertase subtilisin/kexin (type 9) serine ...
M Sampson +4 more
openaire +1 more source